Home Stock

Stock Research: Theravance Biopharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Theravance Biopharma

NMQ:TBPH KYG8807B1068
39
  • Value
    38
  • Growth
    66
  • Safety
    Safety
    23
  • Combined
    30
  • Sentiment
    70
  • 360° View
    360° View
    39
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Theravance Biopharma is a biopharmaceutical company focused on developing medicines for respiratory and neurologic diseases. It operates in the biopharmaceutical industry. Its product, YUPELRI, is used for treating chronic obstructive pulmonary disease (COPD). In the last fiscal year, the company had a market cap of $579 million and a revenue of $64 million, with 97 employees.

more

ANALYSIS: With an Obermatt 360° View of 39 (better than 39% compared with alternatives), overall professional sentiment and financial characteristics for the stock Theravance Biopharma are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Theravance Biopharma. The consolidated Growth Rank has a good rank of 66, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 66% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 70, which means that professional investors are more optimistic about the stock than for 70% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 38, which means that the share price of Theravance Biopharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 62% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 23, which means that the company has a financing structure that is riskier than those of 77% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Capital Growth
Country Cayman Islands
Industry Pharmaceuticals
Size Small
Website theravance.com
Index
NASDAQ
Theravance Biopharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
38 7 29 25
Growth
66 55 61 83
Safety
Safety
23 40 74 17
Sentiment
70 21 20 10
360° View
360° View
39 8 37 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
27 55 77 5
Opinions Change
13 50 50 50
Pro Holdings
n/a 15 1 82
Market Pulse
89 22 13 7
Sentiment
70 21 20 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
38 7 29 25
Growth
66 55 61 83
Safety Safety
23 40 74 17
Combined
30 8 67 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
3 15 7 1
Price vs. Earnings (P/E)
92 1 11 11
Price vs. Book (P/B)
50 60 68 100
Dividend Yield
1 1 1 1
Value
38 7 29 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 100 96 94
Profit Growth
44 26 4 72
Capital Growth
100 9 99 95
Stock Returns
97 65 31 3
Growth
66 55 61 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
63 50 100 1
Refinancing
43 78 94 94
Liquidity
8 1 1 1
Safety Safety
23 40 74 17

Similar Stocks

Discover high‑ranked alternatives to Theravance Biopharma and broaden your portfolio horizons.

Indah Kiat

JKT:INKP
Country: Indonesia
Industry: Paper Products
Size: X-Large
Full Stock Analysis

Equity Group Holdings

NAI:EQTY
Country: Kenya
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

AP Thailand

SET:AP
Country: Thailand
Industry: Real Estate Development
Size: Large
Full Stock Analysis

Astral Foods

JNB:ARL
Country: South Africa
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews